FRAMINGHAM, MA — November 19, 2025 — Leads & Copy — Xenetic Biosciences, Inc. (NASDAQ:XBIO) has extended its collaboration with The Scripps Research Institute to further develop its immuno-oncology technologies targeting difficult-to-treat cancers.
The four-month extension, effective November 1, 2025, continues the partnership with The Scripps Research Institute and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research. The extended collaboration aims to advance Xenetic’s research and development program evaluating the combination of systemic DNase I and CAR T-cell therapies.
XBIO-015, Xenetic’s systemic DNase I candidate, is currently in preclinical development for use in combination with CAR-T cell therapy for hematologic and solid tumors. According to studies by Dr. Stepanov’s lab at Scripps Research, co-administration of DNase I with CAR-T cells has demonstrated significant benefits in lymphoma, metastatic melanoma, and leukemia models. These benefits include reducing tumor burden, decreasing metastatic lesions, and extending survival compared to CAR-T cell monotherapy.
The studies also showed that systemic DNase I-mediated degradation of neutrophil extracellular traps (NETs) enhances CAR-T cell efficacy. This enhancement increases the infiltration of both CAR-T cells and endogenous T cells into tumors and mitigates the immunosuppressive tumor microenvironment (TME).
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, expressed his pleasure in extending the collaboration, emphasizing the value of the Scripps Research team’s partnership. He noted that the encouraging data generated to date warrants further evaluations and that the expertise of the Scripps Research team validates the company’s belief in DNase I’s potential to improve therapeutic responses in patients undergoing CAR-T cell therapy.
Xenetic is progressing its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company has completed preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models. With this success, the program has now advanced to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.
Xenetic Biosciences, Inc. is focused on advancing innovative immuno-oncology technologies that target difficult-to-treat cancers. The company’s proprietary DNase technology aims to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
Source: Xenetic Biosciences, Inc.
